Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 183-192

  Roman, Nicholas O ^a,b   Samulitis, Betty K ^a   Wisner, Lee ^a   Landowski, Terry H ^a   Dorr, Robert T ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Gemcitabine; Imexon; Pancreatic cancer; Ribonucleotide reductase; Synergy

Indexed keywords

CYTIDINE DEAMINASE; DNA; GEMCITABINE; IMEXON; RIBONUCLEOTIDE REDUCTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE MODEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG UPTAKE; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG SYNERGISM; FEMALE; HEXANONES; HUMANS; MICE; MICE, INBRED BALB C; MICE, SCID; PANCREATIC NEOPLASMS; RIBONUCLEOTIDE REDUCTASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 78651094422     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1306-0     Document Type: Article

References (38)

1. A Jemal R Siegel E Ward Y Hao J Xu T Murray MJ Thun 2008 Cancer Statistics, 2008 CA Cancer J Clin 58 71 96 10.3322/CA.2007.0010 18287387 (Pubitemid 351521864)
2. HA Burris III MJ Moore J Andersen MR Green ML Rothenberg MR Modiano, et al. 1997 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403 2413 1:CAS:528:DyaK2sXlsFKksLY%3D 9196156
3. R Hermann G Bodoky T Ruhstaller B Glimelius E Bajeta J Schuller, et al. 2007 Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, Phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group J Clin Oncol 25 2212 2217 10.1200/JCO.2006.09.0886 (Pubitemid 46954645)
4. CM Rocha-Lima 2008 New directions in the management of advanced pancreatic cancer: a review Anticancer Drugs 19 435 446 1:CAS:528: DC%2BD1cXks12gs7w%3D 10.1097/CAD.0b013e3282fc9d11 18418211 (Pubitemid 351556396)
5. MJ Moore D Goldstein J Hamm A Figer JR Hecht S Gallinger, et al. 2007 Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 1960 1966 1:CAS:528: DC%2BD2sXmvVWmsr0%3D 10.1200/JCO.2006.07.9525 17452677 (Pubitemid 46972777)
6. T Dragovich M Gordon D Mendelson L Wong M Modiano HH Chow, et al. 2007 Phase I trial of imexon in patients with advanced malignancy J Clin Oncol 25 1779 1784 1:CAS:528:DC%2BD2sXlvFyktbc%3D 10.1200/JCO.2006.08.9672 17470869 (Pubitemid 46797961)
7. BS Iyengar RT Dorr WA Remers 2004 Chemical basis for the biological activity of imexon and related cyanoaziridines J Med Chem 47 218 223 1:CAS:528:DC%2BD3sXpsFygurg%3D 10.1021/jm030225v 14695835 (Pubitemid 38040505)
8. K Dvorakova CM Payne ME Tome MM Briehl T McClure RT Dorr 2000 Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon Biochem Pharmacol 60 749 758 1:CAS:528:DC%2BD3cXltlWgt78%3D 10.1016/S0006-2952(00)00380-4 10930529 (Pubitemid 30621659)
9. RT Dorr MA Raymond TH Landowski NO Roman S Fukushima 2005 Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines Int J Gastrointest Cancer 36 15 28 1:CAS:528:DC%2BD2MXht1eiu7bJ 10.1385/IJGC:36:1:015 16227632
10. J Scott RT Dorr B Samulitis TH Landowski 2007 Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cells lines Cancer Chemother Pharmacol 59 749 757 1:CAS:528:DC%2BD2sXjt1WmtLw%3D 10.1007/s00280-006-0329-z 17333195 (Pubitemid 46440597)
11. R Loor NJ Nowak ML Manzo HO Douglass TM Chu 1982 Use of pancreas-specific antigen in immunodiagnosis of pancreatic cancer Clin Lab Med 2 567 578 1:STN:280:DyaL3s%2FltF2nsQ%3D%3D 6754226
12. AA Yunis GK Arimura DJ Russin 1977 Human pancreatic carcinoma (MiaPaCa-2) in continuous culture: sensitivity to asparaginase Int J Cancer 19 128 135 1:CAS:528:DyaE2sXmsFCnuw%3D%3D 10.1002/ijc.2910190118 832918 (Pubitemid 8016933)
13. M Lieber J Mazzetta W Nelson-Rees M Kaplan G Todaro 1975 Establishment of a continuous tumor-cell line (Panc-1) from a human carcinoma of the exocrine pancreas Int J Cancer 15 741 747 1:STN:280:DyaE2M7ovVKlsg%3D%3D 10.1002/ijc.2910150505 1140870
14. T Mosmann 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J Immunol Methods 65 55 63 1:STN:280:DyaL2c%2FovFSmtw%3D%3D 10.1016/0022-1759(83)90303-4 6606682
15. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 1:CAS:528:DyaL2cXktlaksLk%3D 10.1016/0065-2571(84)90007-4 6382953
16. MC Bissery D Guenard F Fueritte-Voegelein F Lavelle 1991 Experimental antitumor activity of Taxotere (RP56976, NSC 628503), a Taxol Analogue Cancer Res 51 4845 4852 1:CAS:528:DyaK3MXmt1aqsbg%3D 1680023
17. CJ van Moorsel JR Kroep HM Pinedo G Veerman DA Voorn PE Postmus, et al. 1999 Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors Ann Oncol 10 441 448 10.1023/A:1008301522349 10370787 (Pubitemid 29236422)
18. GW Camiener 1967 Studies of the enzymatic deamination of cytosine arabinoside. II. Properties of the deaminase of human liver Biochem Pharmacol 16 1681 1689 1:CAS:528:DyaF2sXkvFOiur0%3D 10.1016/0006-2952(67)90243-2 4964068
19. B Zhou S Mi X Mo J Shih J Tsai E Hu, et al. 2002 Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells Anticancer Res 22 1369 1377 1:CAS:528:DC%2BD38XmsFWltrY%3D 12168813
20. T Szekeres K Gharehbaghi M Fritzer M Woody A Srivastava B van't Riet, et al. 1994 Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase Cancer Chemother Pharmacol 34 63 66 1:CAS:528:DyaK2cXls12qs74%3D 10.1007/BF00686113 8174204
21. Cobb GW (2002) Introduction to design and analysis of experiments, 1st edn. Wiley, Hoboken
22. ML Clarke JR Mackey SA Baldwin JD Young CE Cass 2002 The role of membrane transporters in cellular resistance to anticancer nucleoside drugs Cancer Treat Res 112 27 47 1:CAS:528:DC%2BD3sXisF2iur0%3D 12481710
23. H Eklund U Uhlin M Färnegårdh DT Logan P Nordlund 2001 Structure and function of the radical enzyme ribonucleotide reductase Prog Biophys Mol Biol 77 177 268 1:CAS:528:DC%2BD38XktVKmtw%3D%3D 10.1016/S0079-6107(01)00014-1 11796141 (Pubitemid 34131599)
24. A Holmgren 1989 Thioredoxin and glutaredoxin systems J Biol Chem 264 13963 13966 1:CAS:528:DyaL1MXlsVyqtbk%3D 2668278
25. NM Cerqueira S Pereira PA Fernandes MJ Ramos 2005 Overview of ribonucleotide reductase inhibitors: an appealing target in anti-tumour therapy Curr Med Chem 12 1283 1294 1:CAS:528:DC%2BD2MXksFahtrc%3D 10.2174/ 0929867054020981 15974997 (Pubitemid 40711424)
26. V Heinemann LW Hertel GB Grindey W Plunkett 1988 Comparison of the cellular pharmacokinetics and toxicity of 2, 2-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine Cancer Res 48 4024 4031 1:CAS:528: DyaL1cXlt1ajurc%3D 3383195
27. AR Van Rompay M Johansson A Karlsson 2000 Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases Pharmacol Ther 87 189 198 10.1016/S0163-7258(00)00048-6 11008000
28. VW Ruiz van Haperen G Veerman JB Vermorken GJ Peters 1993 2'-2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Biochem Pharmacol 46 762 766 1:STN:280:DyaK3szntFCruw%3D%3D 10.1016/0006-2952(93)90566-F 8363650 (Pubitemid 23262974)
29. V Heinemann L Schulz RD Issels W Plunkett 1995 Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism Semin Oncol 22 11 18 1:CAS:528:DyaK2MXpsFGntbc%3D 7481839
30. W Plunkett P Huang CE Searcy V Gandhi 1996 Gemcitabine: preclinical pharmacology and mechanisms of action Semin Oncol 23 3 15 1:CAS:528: DyaK28XmvFWrtbg%3D 8893876
31. M Kolberg KR Strand P Graff KK Andersson 2004 Structure, function and mechanism of ribonucleotide reductases Biochim Biophys Acta 1699 1 34 1:CAS:528:DC%2BD2cXkt1Cmtr4%3D 15158709
32. S Pereira PA Fernandes MJ Ramos 2004 Mechanism for ribonucleotide reductase inactivation by the anticancer drug gemcitabine J Comput Chem 25 1286 1294 1:CAS:528:DC%2BD2cXltFOjurc%3D 10.1002/jcc.20054 15139041
33. J Shao B Zhou B Chu Y Yen 2006 Ribonucleotide reductase inhibitors and future drug design Curr Cancer Drug Targets 6 409 431 1:CAS:528: DC%2BD28XnslCmsL8%3D 10.2174/156800906777723949 16918309 (Pubitemid 44033390)
34. IK Larsen C Cornett M Karlsson M Sahlin BM Sjöberg 1992 Caracemide, a site-specific irreversible inhibitor of protein R1 of Escherichia coli ribonucleotide reductase J Biol Chem 267 12627 12631 1:STN:280: DyaK38zhs12ntw%3D%3D 1618768
35. EC Moore TL Loo 1984 Inhibition of ribonucleotide reductase by caracemide Cancer Treat Rep 68 1293 1294 1:CAS:528:DyaL2cXmt1ahs7s%3D 6395952
36. RA Newman D Farquhar K Lu R Meyn EC Moore S Massia, et al. 1986 Biochemical pharmacology of N-acetyl-N-(methylcarbamoyloxy)-N'-methylurea (caracemide: NSC-253272) Biochem Pharmacol 35 2781 2787 1:CAS:528: DyaL28Xls1CmtLc%3D 10.1016/0006-2952(86)90190-5 3527174 (Pubitemid 16051525)
37. SL Smith KT Douglas 1989 Stereoselective, strong inhibition of ribonucleotide reductase from E. coli by cisplatin Biochem Biophys Res Comm 162 715 723 1:CAS:528:DyaL1MXltVylsb8%3D 10.1016/0006-291X(89)92369-3 2667519
38. Cohen SJ, Zalupski MM, Modiano MR, Conkling PR, Patt YZ, Davis P, et al. (2009) A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer. Cancer Chemother Pharmacol (Epub)